15 news items
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
weighing 63kg or greater adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
REGN
SNY
31 May 24
-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually
FDA Extends Priority Review Deadline For Regeneron Pharmaceuticals And Sanof's Dupixent For The Treatment Of COPD Patients With Type 2 Inflammation To September 2024
REGN
SNY
31 May 24
License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
of Dupixent (dupilumab) in the European Union (EU) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. The European Commission is expected to announce a final
uwddb7fgt71cu14c4rrr59riiz1qo7687p8jt6yds4 v3wbwzb1
REGN
31 May 24
with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns
s7c7561u
REGN
31 May 24
with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns
gsq16xroz1g9budvzoi1ozxcq0egwvmledftdix4ln85z5kf taa3dttsix
REGN
SNY
20 May 24
% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
y8bg8qm5lv0moszu
REGN
20 May 24
to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
y6y4c13ao 8lf8188mqdq04g89layw3gftlo69f8wsbv
REGN
20 May 24
exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type
xwssb99slw6vqnach2d2rk2 j3p
REGN
SNY
13 May 24
muexvx3
REGN
13 May 24
12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). The target action date for the FDA decision
ofn24pbvj5k3r5jw3e18foqinhzv us57cp2dicp7apyt5
REGN
2 May 24
Application (sBLA) for Dupixent as an add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD
m6pcqogm025efp5 yu8n3pqi
REGN
24 Apr 24
Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
qumunaicby2c337z4wqjh27br102ozx9921dlhrh2bs
AMGN
AZN
REGN
17 Apr 24
an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive
- Prev
- 1
- Next